Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company imports and sells medicines.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5,177 | 5,288 | 6,855 | 8,257 | 9,189 | 7,831 | 8,048 | +7.6% |
| Total COGS | 2,494 | 2,850 | 3,400 | 4,208 | 4,033 | 3,369 | 4,087 | +8.6% |
| Gross Profit | 2,683 | 2,439 | 3,454 | 4,049 | 5,156 | 4,462 | 3,961 | +6.7% |
| Gross Margin | 51.8% | 46.1% | 50.4% | 49.0% | 56.1% | 57.0% | 49.2% | |
| 1,045 | 1,300 | 1,312 | 2,153 | 1,715 | 2,561 | 2,536 | +15.9% | |
| EBITDA | 1,638 | 1,139 | 2,143 | 1,896 | 3,441 | 1,901 | 1,425 | -2.3% |
| EBITDA Margin | 31.6% | 21.5% | 31.3% | 23.0% | 37.5% | 24.3% | 17.7% | |
| Total D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| EBIT / Operating Income | 1,638 | 1,139 | 2,143 | 1,896 | 3,441 | 1,901 | 1,425 | -2.3% |
| Total Interest Income | 9 | 0 | 0 | 1 | 3 | 17 | 5 | -7.3% |
| Total Interest Expense | 42 | 1 | 20 | 113 | 73 | 6 | 21 | -10.6% |
| 0 | 0 | 2 | 0 | 30 | 147 | 18 | nmf | |
| Profit Before Tax | 1,605 | 1,138 | 2,125 | 1,785 | 3,402 | 1,764 | 1,391 | -2.3% |
| Total Income Tax | 0 | 0 | 191 | 164 | 257 | 273 | 261 | +8.1% |
| Net Profit / (Loss) | 1,605 | 1,138 | 1,933 | 1,621 | 3,144 | 1,491 | 1,130 | -5.7% |
| Net Margin | 31.0% | 21.5% | 28.2% | 19.6% | 34.2% | 19.0% | 14.0% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →